Xenon Pharmaceuticals Inc (XENE)

$15.97 0.00 (0.00%)

9:00 EST XENE Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 281.27M

PE Ratio -10.65

EPS -1.5

Volume (Avg. Vol.) 1

Day's Range 15.97 - 15.97

52-Week Range 7.00 - 18.45

Dividend & Yield N/A (N/A)

XENE Stock Predictions, Articles, and Xenon Pharmaceuticals Inc News

From InvestorPlace
From the Web

Xenon Pharmaceuticals Inc (XENE) Plunges on Acne Drug Flop

By William White, InvestorPlace Writer Mar 24, 2017

Xenon Pharmaceuticals (XENE) stock was falling hard on Friday following results from a recent study of its acne drug XEN801.

The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs

From Benzinga Dec 4, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 3) Atara Biotherapeutics Inc (...

Xenon Pharmaceuticals Inc (XENE) Q3 2020 Earnings Call Transcript

From The Motley Fool Nov 7, 2020

XENE earnings call for the period ending September 30, 2020.

Xenon Pharmaceuticals Inc (XENE) Q2 2020 Earnings Call Transcript

From The Motley Fool Aug 7, 2020

XENE earnings call for the period ending June 30, 2020.

The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions

From Benzinga Nov 29, 2020

Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday. The week kickstarted with...

Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue Estimates

From Zacks Investment Research Nov 5, 2020

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -66.67% and -36.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga's Top Upgrades, Downgrades For October 2, 2020

From Benzinga Oct 2, 2020

Upgrades According to Evercore ISI Group, the prior rating for Splunk Inc (NASDAQ: SPLK) was changed from In-Line to Outperform. Splunk earned $0.33 in the second quarter,...

Navellier Ratings

Total Grade

Sell